News

Fleet Bioprocessing provides flexible, end-to-end contract lateral flow assay development, supporting projects from critical reagent screening and proof of concept through optimisation, performance verification and transfer to manufacture.

Sustainability in lateral flow testing is broader than material substitution. This article explores how material design, reagent strategy, manufacturing yield, performance testing, supply chain choices and at-source testing can reduce waste across the full lateral flow test lifecycle.

Performance verification is the stage at which a lateral flow assay moves from development understanding to formal analytical evidence. This article explains how intended use and design inputs shape verification strategy, how CLSI-guided studies are structured, and why robust documentation is critical for transfer, submission, and product readiness.

Lateral Flow Assays (LFAs) may look simple, but successful development is far from straightforward. Behind reliable, consistent performance lies careful control of multiple interacting variables that can otherwise introduce hidden risk. Too often, development challenges surface late, when changes are costly, timelines slip and verification efforts fail. The difference between a smooth path to market and repeated re-design frequently comes down to early technical decisions and

Fleet Bioprocessing launches contract lateral flow device development, offering end-to-end LFD feasibility, optimisation, verification and validation services.